Abstract 235P
Background
Anal cancer despite its low incidence worldwide is considered a disease with social and family impact of increasing importance in our environment compared to tumors of the colon and rectum coupled with the lack of epidemiological data on this pathology in our Colombian region.
Methods
This work describes the epidemiological characteristics of anal cancer through a retrospective analysis of the patients treated in Oncólogos del Occidente SAS from Colombian Coffee Axis diagnosed between 01/01/2001 and 31/12/2017.
Results
Oncological records were reviewed at the Institution obtaining 360 patients (1.03%) with anal cancer; mean age 62.8 (range 32-92 - SD 12.47), 44% women and 94% urban area; 67% in various trades; clinical stage II-A 35%, stage IIIA 19%, stage IIIB 14% and 7% stage IV; squamous histology including basaloid 85% and adenocarcinoma 14%; Well differentiated 60% and moderately 21%; 7% underwent radical perineal surgery, 78% received Neoadjuvant chemoradiation and 7% only radiotherapy; 11% presented tumor relapse and 21% persistence; 57% of local type and of these 82% did not receive rescue treatment and 4% only Radiotherapy; 83% did not present GAP in their radiotherapy treatment with an average of 4.7 days in the remaining 17%; 68% received Nigro scheme initially and 4% based on fluoropyrimidines and platinum, as well as 5% as a rescue scheme; 88% with functional status greater than or equal to 80%; total mean dose of radiotherapy of 45.47 Gys with 81% of these completing the treatment; the mean follow-up was 36,817 months (range: 0-28 months, SD: 42,165 months); the median survival was not reached and the overall survival at 5 years was 58%, others data for survival were 45% for stage III and 71% stage II, 68% without relapse, 51% with relapse and 36% with persistence, 64% male and 54% female, 65% for Epidermoid and 23% for adenocarcinoma, 61% with total dose less than 45 Gys and 79% in greater than 55 Gys.
Conclusions
These results reflect the epidemiological profile of anal cancer in a specific area of Colombia and the importance of the multidisciplinary treatment group in order to improve therapeutic results.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
C.R. Villegas Mejia: Non-Financial Interests, Institutional, Invited Speaker: Oncologos del occidente. M. Villegas Jaramillo: Non-Financial Interests, Personal, Invited Speaker: Private. P. Villegas Jaramillo: Non-Financial Interests, Institutional, Invited Speaker: Universidda de Manizales.